CVRx, Inc. (CVRX) News
Filter CVRX News Items
CVRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVRX News Highlights
- For CVRX, its 30 day story count is now at 5.
- Over the past 19 days, the trend for CVRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CVRX are BEAT, DEC and DRUG.
Latest CVRX News From Around the Web
Below are the latest news stories about CVRX INC that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceMINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast. A live audio webcast of the c |
CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
CVRx receives FDA approval for expanded labeling of BarostimU.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF dataMINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has approved revised Instructions For Use (IFU) for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. “We are very pleased to receive this important validat |
CVRx (CVRX) Is Up 10.17% in One Week: What You Should KnowDoes CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
CVRx (CVRX) is on the Move, Here's Why the Trend Could be SustainableCVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most OnMaybe you could find out which stocks a well-known company that has been successful for a long time really likes -- a company such as Johnson & Johnson (NYSE: JNJ). Here are the three stocks that J&J is betting the most on. As of Sept. 30, 2023, Johnson & Johnson's biggest investment was in Legend Biotech (NASDAQ: LEGN). |
CVRx to Present at the 35th Annual Piper Sandler Healthcare ConferenceMINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. The Company is scheduled to present at 11:00am Eastern Time the same day via webcast. A live aud |
CMS Increases Outpatient Payment for Barostim ProcedureMINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. In the 2024 OPPS final rule, Barostim was reassigned to New Technology APC 1580, which carries an average paymen |
What Makes CVRx (CVRX) a New Strong Buy StockCVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |